Monitor for Phase 2 trial initiation of SCY-770 in ADPKD, which is the key near-term catalyst. Dr. Burke's nephrology expertise supports the pipeline but does not change the clinical-stage risk profile.
Price Chart
Executive Summary
SCYNEXIS appointed Steven K. Burke, M.D., a seasoned nephrology drug development executive, to its Board of Directors effective September 18, 2026. Dr. Burke, who serves as Chief R&D Officer and CMO at Akebia Therapeutics, brings over 30 years of biopharma experience as the company prepares to enter Phase 2 with its lead ADPKD candidate SCY-770. This is a routine board appointment with no financial data or guidance provided.
Key Facts
- Steven K. Burke, M.D., appointed to the Board effective September 18, 2026
- Dr. Burke is Senior VP, Chief R&D Officer and CMO at Akebia Therapeutics since 2021
- Appointed to the Nominating and Corporate Governance Committee
- Initial stock option grant: 5,750 shares at $4.46 exercise price (closing price on grant date)
- Initial RSU grant: 5,750 shares, vesting 1/3 per year over 3 years
- Annual retainer: $45,000; committee retainer: $5,000
- Company preparing to enter Phase 2 with SCY-770 for ADPKD
- SCY-770 has Orphan Drug Designation from FDA for ADPKD
Financial Impact
Director compensation disclosed: $45,000 annual retainer plus $5,000 committee retainer, initial equity grants of 5,750 option shares and 5,750 RSUs, and annual equity grants of 2,875 options and 2,875 RSUs. No material financial impact.
Risk Factors
- Clinical-stage biotech with no approved products generating revenue
- SCY-770 Phase 2 trial results are binary and could fail
- Stock price volatility typical for pre-revenue biotech companies
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000035 |
| Document: scyx-ex99_1.htm | 0001178253-26-000035 |
| Document: 0001178253-26-000035-index-headers.html | 0001178253-26-000035 |
| Document: 0001178253-26-000035-index.html | 0001178253-26-000035 |
| Document: 0001178253-26-000035.txt | 0001178253-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 8d ago | Press Release | $3.81 $3.86 | ▲ +1.31% | ▲ +0.61% | $3.76 (−1.23%) |
Oct 6, 2026 24d ago | Press Release | $4.84 $3.99 | ▼ −17.56% | ▼ −17.42% | $3.76 (−22.25%) |
Sep 28, 2026 4w ago | Press Release | $4.62 $5.03 | ▲ +8.87% | ▲ +7.67% | $3.76 (−18.55%) |
Sep 22, 2026 5w ago | 8-K | $4.86 $4.66 | ▼ −4.12% | ▼ −2.93% | $3.76 (−22.57%) |
Sep 10, 2026 7w ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $3.76 (−19.93%) |
Jun 26, 2026 17w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $3.76 (−2.76%) |
May 22, 2026 22w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $3.76 (−30.93%) |
May 11, 2026 24w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $3.76 (+39.69%) |
Apr 20, 2026 27w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $3.76 (−55.62%) |
Mar 31, 2026 30w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $3.76 (−48.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers